Successful Pregnancy in a Patient With Dermatitis Herpetiformis Treated With Low-Dose Dapsone

Publisher Website
Google Scholar
Abstract
To the Editor.— Dermatologists are increasingly using dapsone to treat a wide variety of serious cutaneous diseases. Inevitably, the problem of dapsone therapy in pregnancy will arise. Recently, a 33-year-old patient who had severe dermatitis herpetiformis requiring dapsone therapy became pregnant. Several telephone inquires disclosed a general lack of clinical experience with the use of sulfones in pregnancy. The disease was of 16 years' duration. The use of all other therapeutic modalities, including sulfapyridine, a glutenfree diet, adrenal steroids given for systemic effect, pyribenzamine, had either been unsuccessful or not tolerated. The patient required 25 to 50 mg/day of oral dapsone to control her disease reasonably well. The Physicians' Desk Reference statement was relatively ambiguous. Communications with the manufacturer, David P. Jacobus, MD, of Jacobus Pharmaceutical Co Inc, Princton, NJ, indicated a lack of experience with dapsone for the treatment of dermatitis herpetiformis during pregnancy. However, two articles on the

This publication has 1 reference indexed in Scilit: